‘Altruistic’ COVID-19 Prices And Biopharma’s Reputation: Is The Benefit Important?

Health policy experts debate the public opinion benefit of pricing at cost during a National Pharmaceutical Council webinar on pricing COVID-19 treatments and vaccines.